Jean-Pierre Bronowicki

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +8

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook et al. · Journal of Hepatology · 2016 · 385 citations · Full text

Medicine, Pharmacotherapy, Clinical Pharmacology +2

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

Marc Bourlière, Jean-Pierre Bronowicki, Victor de Lédinghen et al. · The Lancet Infectious Diseases · 2015 · 281 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Jean-François H. Geschwind, Masatoshi Kudo, Jorge A. Marrero et al. · Radiology · 2016 · 124 citations

Medicine, Oncology, Pharmacotherapy +17